Phil Nadeau
Stock Analyst at TD Cowen
(4.32)
# 1,349
Out of 5,004 analysts
787
Total ratings
47.7%
Success rate
7.1%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics | Reiterated: Buy | n/a | $14.81 | - | 1 | Sep 24, 2026 | |
| CABA Cabaletta Bio | Reiterated: Buy | n/a | $2.07 | - | 16 | Sep 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $120 | $60.26 | +99.14% | 85 | Aug 20, 2026 | |
| ANNX Annexon | Reiterated: Buy | n/a | $3.64 | - | 19 | Aug 12, 2026 | |
| IPSC Century Therapeutics | Reiterated: Buy | n/a | $1.67 | - | 5 | Aug 12, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | n/a | $10.76 | - | 22 | Aug 12, 2026 | |
| MLTX MoonLake Immunotherapeutics | Reiterated: Buy | n/a | $12.04 | - | 20 | Aug 10, 2026 | |
| NKTX Nkarta | Reiterated: Buy | n/a | $2.75 | - | 2 | Aug 10, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | n/a | $2.68 | - | 43 | Aug 6, 2026 | |
| EDIT Editas Medicine | Reiterated: Buy | n/a | $2.58 | - | 28 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $44.75 | - | 18 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $10.66 | - | 21 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $130 | $98.66 | +31.77% | 37 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $18.20 | - | 22 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $525 → $550 | $526.19 | +4.52% | 87 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $200 → $220 | $138.40 | +58.96% | 57 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $215 → $225 | $227.60 | -1.14% | 55 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $6.00 | - | 13 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $29.54 | - | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.99 | - | 6 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.81 | n/a | 18 | Mar 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0004 | n/a | 27 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $29.38 | n/a | 31 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.92 | n/a | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $9.57 | n/a | 3 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 → $75 | $150.93 | n/a | 44 | Feb 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.77 | n/a | 12 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.65 | n/a | 7 | Aug 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $2.60 | n/a | 6 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $385 | $788.04 | n/a | 40 | Feb 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.08 | n/a | 14 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 → $16 | $0.000001 | n/a | 14 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $205 | $414.61 | n/a | 1 | Jul 26, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.80 | n/a | 1 | May 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $185 | $475.45 | n/a | 5 | Apr 28, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $18.67 | n/a | 1 | Aug 7, 2015 |
Cullinan Therapeutics
Sep 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $14.81
Upside: -
Cabaletta Bio
Sep 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.07
Upside: -
BioMarin Pharmaceutical
Aug 20, 2026
Reiterated: Buy
Price Target: $120
Current: $60.26
Upside: +99.14%
Annexon
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.64
Upside: -
Century Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.67
Upside: -
Kura Oncology
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $10.76
Upside: -
MoonLake Immunotherapeutics
Aug 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $12.04
Upside: -
Nkarta
Aug 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.75
Upside: -
Voyager Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.68
Upside: -
Editas Medicine
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.58
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $44.75
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $10.66
Upside: -
Aug 4, 2026
Rated: Buy
Price Target: $130
Current: $98.66
Upside: +31.77%
Aug 4, 2026
Reiterated: Buy
Price Target: n/a
Current: $18.20
Upside: -
Aug 4, 2026
Rated: Buy
Price Target: $525 → $550
Current: $526.19
Upside: +4.52%
Jul 31, 2026
Rated: Buy
Price Target: $200 → $220
Current: $138.40
Upside: +58.96%
Jul 30, 2026
Rated: Buy
Price Target: $215 → $225
Current: $227.60
Upside: -1.14%
May 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.00
Upside: -
May 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $29.54
Upside: -
Apr 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.99
Upside: -
Mar 9, 2025
Reiterated: Buy
Price Target: n/a
Current: $8.81
Upside: n/a
Nov 13, 2024
Rated: Hold
Price Target: n/a
Current: $0.0004
Upside: n/a
Oct 31, 2024
Reiterated: Buy
Price Target: n/a
Current: $29.38
Upside: n/a
Mar 22, 2024
Rated: Hold
Price Target: n/a
Current: $3.92
Upside: n/a
Feb 13, 2023
Downgraded: Hold
Price Target: n/a
Current: $9.57
Upside: n/a
Feb 4, 2021
Reiterated: Buy
Price Target: $80 → $75
Current: $150.93
Upside: n/a
Nov 9, 2020
Reiterated: Buy
Price Target: n/a
Current: $8.77
Upside: n/a
Aug 7, 2019
Reiterated: Buy
Price Target: n/a
Current: $1.65
Upside: n/a
Feb 26, 2019
Initiated Coverage: Buy
Price Target: n/a
Current: $2.60
Upside: n/a
Feb 6, 2019
Rated: Hold
Price Target: $385
Current: $788.04
Upside: n/a
Jan 17, 2019
Reiterated: Hold
Price Target: n/a
Current: $3.08
Upside: n/a
Nov 2, 2018
Reiterated: Buy
Price Target: $2 → $16
Current: $0.000001
Upside: n/a
Jul 26, 2018
Rated: Buy
Price Target: $205
Current: $414.61
Upside: n/a
May 3, 2016
Reiterated: Hold
Price Target: n/a
Current: $1.80
Upside: n/a
Apr 28, 2016
Reiterated: Buy
Price Target: $185
Current: $475.45
Upside: n/a
Aug 7, 2015
Reiterated: Hold
Price Target: n/a
Current: $18.67
Upside: n/a